Ascend Wellness (OTCMKTS:AAWH – Get Free Report) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.
Earnings & Valuation
This table compares Ascend Wellness and Milestone Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ascend Wellness | $500.58 million | 0.15 | -$118.19 million | ($0.57) | -0.63 |
| Milestone Pharmaceuticals | $1.55 million | 41.77 | -$63.06 million | ($0.69) | -0.75 |
Institutional and Insider Ownership
17.3% of Ascend Wellness shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 21.9% of Ascend Wellness shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for Ascend Wellness and Milestone Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ascend Wellness | 0 | 1 | 0 | 0 | 2.00 |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
Milestone Pharmaceuticals has a consensus price target of $6.40, indicating a potential upside of 1,130.77%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Ascend Wellness.
Profitability
This table compares Ascend Wellness and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ascend Wellness | -23.49% | N/A | -11.12% |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
Risk & Volatility
Ascend Wellness has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
Summary
Milestone Pharmaceuticals beats Ascend Wellness on 8 of the 15 factors compared between the two stocks.
About Ascend Wellness
Ascend Wellness Holdings is a U.S. cannabis company that cultivates, processes, and sells cannabis products in regulated state markets. Its business combines cultivation and manufacturing facilities with a network of retail dispensaries. The company offers products including cannabis flower, edibles, concentrates, and vape products. Its portfolio includes brands such as Ozone and Simply Herb, alongside products from other suppliers sold through its retail stores. Founded in 2018, Ascend has developed operations across markets including Illinois, Michigan, Ohio, Massachusetts, New Jersey, and Pennsylvania.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
Receive News & Ratings for Ascend Wellness Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascend Wellness and related companies with MarketBeat.com's FREE daily email newsletter.
